Distinguished in Ectodermal Dysplasia Neurosensory Deafness

Julia V. Mayerle

Munich, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Ectodermal Dysplasia Neurosensory Deafness
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Julia Mayerle practices in Munich, Germany. Ms. Mayerle is rated as a Distinguished expert by MediFind in the treatment of Ectodermal Dysplasia Neurosensory Deafness. Her top areas of expertise are Hereditary Pancreatitis, Chronic Pancreatitis, Acute Pancreatitis, Gallbladder Removal, and Lithotripsy.

Her clinical research consists of co-authoring 347 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Ectodermal Dysplasia Neurosensory Deafness.

Gender
Female

Locations

Munich, BY, Germany
Other Locations
Bayern, BY, Germany
Heidelberg, BW 69120, Germany
Erlangen, BY, Germany
Mecklenburg, MV, Germany
Greifswald, MV 17475, Germany
Tuebingen, BW, Germany
Ernst, RP, Germany
Giessen, HE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients
A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients
Enrollment Status: Recruiting
Publish Date: June 14, 2024
Intervention Type: Combination product
Study Drug: Atezolizumab Injection, Bevacizumab Injection
Study Phase: Phase 2
Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis
Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis
Enrollment Status: Completed
Publish Date: March 27, 2020
Intervention Type: Other, Dietary supplement, Drug
Study Phase: Phase 3
Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-
Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-
Enrollment Status: Completed
Publish Date: September 20, 2019
Intervention Type: Dietary supplement
Study Phase: Phase 2
TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
Enrollment Status: Completed
Publish Date: September 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

347 Total Publications

Response to 'Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?'
Response to 'Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?'
Journal: Gut
Published: September 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mayerle's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 50 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile